Ceribell的2025年收入增长了36%,达到8 910万美元,这是由林业发展局和美联储RAMP批准的,预计2026年的收入为11 100万美元-115亿美元,尽管损失了53 400万美元。 CeriBell's 2025 revenue rose 36% to $89.1 million, driven by FDA and FedRAMP approvals, with 2026 revenue projected at $111M–$115M despite a $53.4M loss.

据CeriBell报告,2025年第4季度收入为2 480万美元,年同比增长34%,2025年全年收入达8 910万美元,增长36%。 CeriBell reported Q4 2025 revenue of $24.8 million, a 34% year-over-year increase, with full-year 2025 revenue reaching $89.1 million, up 36%. 公司获得了FDA 510（k）批准，针对新生儿/儿科癫痫和谵妄算法，获得中风监测突破性设备认证，并获得FedRAMP High授权，可覆盖市场规模扩大至35亿美元。 The company achieved FDA 510(k) clearances for neonatal/pediatric seizure and delirium algorithms, a Breakthrough Device designation for stroke monitoring, and FedRAMP High authorization, expanding its addressable market to $3.5 billion. 年底共有647个医院账户和1.593亿美元现金。 It ended the year with 647 hospital accounts and $159.3 million in cash. 尽管损失净额为5 340万美元,该公司预计2026年的收入在1.11亿美元至1.15亿美元之间,原因是产品采用和监管进展强劲。 Despite a net loss of $53.4 million, the company projected 2026 revenue between $111 million and $115 million, citing strong product adoption and regulatory progress.